In particular, MET protein levels increase in metaplasia-dysplasia-adenocarcinoma evolution in esophageal cancer [10], while higher levels of HGF are detectable during the carcinogenesis of gliomas [9], breast cancers, osteosarcomas, and melanomas [11,12]. This evidence concerns the gene MET and breast carcinoma.